Site-Specific Conjugation of Auristatins onto Engineered scFv Using Second Generation Maleimide to Target HER2-positive Breast Cancer in Vitro-Reference-Cited by-同舟云学术

Site-Specific Conjugation of Auristatins onto Engineered scFv Using Second Generation Maleimide to Target HER2-positive Breast Cancer in Vitro

Published:2018-10-23 Issue:11 Volume:29 Page:3516-3521
ISSN:1043-1802
Container-title:Bioconjugate Chemistry
language:en
Short-container-title:Bioconjugate Chem.

Author:

Aubrey Nicolas¹^ORCID,Allard-Vannier Emilie²^ORCID,Martin Camille³^ORCID,Bryden Francesca³,Letast Stéphanie³,Colas Cyril⁴⁵^ORCID,Lakhrif Zineb¹,Collinet Nils²,Dimier-Poisson Isabelle¹,Chourpa Igor²^ORCID,Viaud-Massuard Marie-Claude³^ORCID,Joubert Nicolas³^ORCID

Affiliation:

1. ISP UMR 1282, INRA, Université de Tours, Team BioMAP, 31 avenue Monge, 37200 Tours, France

2. NMNS EA 6295, Université de Tours, 31 avenue Monge, 37200 Tours, France

3. GICC EA7501, Université de Tours, Team IMT, 31 avenue Monge, 37200 Tours, France

4. ICOA UMR 7311, Université d’Orléans, CNRS, rue de Chartres, 45067 Orléans, France

5. CBM UPR 4311, CNRS, Université d’Orléans, rue Charles Sadron, 45071 Orléans, France

Funder

Agence Nationale de la Recherche

Ligue Contre le Cancer

Universit? Fran?ois-Rabelais

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Pharmaceutical Science,Pharmacology,Biomedical Engineering,Bioengineering,Biotechnology

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.bioconjchem.8b00668

Reference25 articles.

1. Towards antibody-drug conjugates and prodrug strategies with extracellular stimuli-responsive drug delivery in the tumor microenvironment for cancer therapy

2. Strategies and challenges for the next generation of antibody–drug conjugates

3. Antibody-drug conjugates: Design and development for therapy and imaging in and beyond cancer, LabEx MAbImprove industrial workshop, July 27–28, 2017, Tours, France

4. https://clinicaltrials.gov/.

5. Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radiation therapy, tissue radiosensitization, and potential synergism in the era of novel antibody-drug conjugates;Critical Reviews in Oncology/Hematology;2024-03

2. Reforming solid tumor treatment: the emerging potential of smaller format antibody-drug conjugate;Antibody Therapeutics;2024-02-16

3. Branched pegylated linker-auristatin to control hydrophobicity for the production of homogeneous minibody-drug conjugate against HER2-positive breast cancer;Journal of Controlled Release;2024-02

4. Heterobifunctional Cross-Linker with Dinitroimidazole and N-Hydroxysuccinimide Ester Motifs for Protein Functionalization and Cysteine–Lysine Peptide Stapling;Organic Letters;2023-12-07

5. CSPG4 as a target for the specific killing of triple-negative breast cancer cells by a recombinant SNAP-tag-based antibody-auristatin F drug conjugate;Journal of Cancer Research and Clinical Oncology;2023-07-11